Cargando…

影像计划和实时引导肺癌穿刺活检在生物标志物检测中的进展

With the progress of targeted therapy and immunotherapy for lung cancer, the clinical demand for lung biopsy is increasing. An ideal biopsy specimen can be used not only for histopathological diagnosis, but also for biomarker detection. The ideal biopsy specimen should meet two requirements, includi...

Descripción completa

Detalles Bibliográficos
Autores principales: BAI, Gengshen, ZHU, Bingyin, MA, Jun, LI, Yongchun, HUANG, Gang, MA, Yaqiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558762/
https://www.ncbi.nlm.nih.gov/pubmed/37752543
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.15
_version_ 1785117351198326784
author BAI, Gengshen
ZHU, Bingyin
MA, Jun
LI, Yongchun
HUANG, Gang
MA, Yaqiong
author_facet BAI, Gengshen
ZHU, Bingyin
MA, Jun
LI, Yongchun
HUANG, Gang
MA, Yaqiong
author_sort BAI, Gengshen
collection PubMed
description With the progress of targeted therapy and immunotherapy for lung cancer, the clinical demand for lung biopsy is increasing. An ideal biopsy specimen can be used not only for histopathological diagnosis, but also for biomarker detection. The ideal biopsy specimen should meet two requirements, including more than 60 mm(2) of tumor tissue and containing more than 20% of tumor cells. In order to obtain ideal lung cancer biopsy specimens, advanced imaging techniques are needed to help. In this article, we reviewed the requirements for biopsy specimens based on biomarker detection, as well as the current status and research progress of using imaging techniques for preoperative planning and intraoperative real time guidance of lung cancer biopsy.
format Online
Article
Text
id pubmed-10558762
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial board of Chinese Journal of Lung Cancer
record_format MEDLINE/PubMed
spelling pubmed-105587622023-10-08 影像计划和实时引导肺癌穿刺活检在生物标志物检测中的进展 BAI, Gengshen ZHU, Bingyin MA, Jun LI, Yongchun HUANG, Gang MA, Yaqiong Zhongguo Fei Ai Za Zhi Review With the progress of targeted therapy and immunotherapy for lung cancer, the clinical demand for lung biopsy is increasing. An ideal biopsy specimen can be used not only for histopathological diagnosis, but also for biomarker detection. The ideal biopsy specimen should meet two requirements, including more than 60 mm(2) of tumor tissue and containing more than 20% of tumor cells. In order to obtain ideal lung cancer biopsy specimens, advanced imaging techniques are needed to help. In this article, we reviewed the requirements for biopsy specimens based on biomarker detection, as well as the current status and research progress of using imaging techniques for preoperative planning and intraoperative real time guidance of lung cancer biopsy. Editorial board of Chinese Journal of Lung Cancer 2023-08-20 /pmc/articles/PMC10558762/ /pubmed/37752543 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.15 Text en 版权所有 © 2023《中国肺癌杂志》编辑部 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle Review
BAI, Gengshen
ZHU, Bingyin
MA, Jun
LI, Yongchun
HUANG, Gang
MA, Yaqiong
影像计划和实时引导肺癌穿刺活检在生物标志物检测中的进展
title 影像计划和实时引导肺癌穿刺活检在生物标志物检测中的进展
title_full 影像计划和实时引导肺癌穿刺活检在生物标志物检测中的进展
title_fullStr 影像计划和实时引导肺癌穿刺活检在生物标志物检测中的进展
title_full_unstemmed 影像计划和实时引导肺癌穿刺活检在生物标志物检测中的进展
title_short 影像计划和实时引导肺癌穿刺活检在生物标志物检测中的进展
title_sort 影像计划和实时引导肺癌穿刺活检在生物标志物检测中的进展
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558762/
https://www.ncbi.nlm.nih.gov/pubmed/37752543
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.15
work_keys_str_mv AT baigengshen yǐngxiàngjìhuàhéshíshíyǐndǎofèiáichuāncìhuójiǎnzàishēngwùbiāozhìwùjiǎncèzhōngdejìnzhǎn
AT zhubingyin yǐngxiàngjìhuàhéshíshíyǐndǎofèiáichuāncìhuójiǎnzàishēngwùbiāozhìwùjiǎncèzhōngdejìnzhǎn
AT majun yǐngxiàngjìhuàhéshíshíyǐndǎofèiáichuāncìhuójiǎnzàishēngwùbiāozhìwùjiǎncèzhōngdejìnzhǎn
AT liyongchun yǐngxiàngjìhuàhéshíshíyǐndǎofèiáichuāncìhuójiǎnzàishēngwùbiāozhìwùjiǎncèzhōngdejìnzhǎn
AT huanggang yǐngxiàngjìhuàhéshíshíyǐndǎofèiáichuāncìhuójiǎnzàishēngwùbiāozhìwùjiǎncèzhōngdejìnzhǎn
AT mayaqiong yǐngxiàngjìhuàhéshíshíyǐndǎofèiáichuāncìhuójiǎnzàishēngwùbiāozhìwùjiǎncèzhōngdejìnzhǎn